Jun
2026
Shanghai New International Expo Center
Visit us
stand E2C71, Contract Services
Polpharma
Exhibitor at CPHI & PMEC China 2026
About Us
Categories
-
Country/Region:Poland
-
On CPHI since:2015
-
Certificates:4
-
Employees:5000+
Company types
Event information
CPHI & PMEC China 2026
-
16 Jun 2026 - 18 Jun 2026
-
Shanghai New International Expo Center
-
Visit us at stand E2C71, Contract Services
Products Featured at CPHI & PMEC China 2026
-
Product Acenocoumarol
Therapeutic Area: Cardiovascular system
EU DMF
Indication: Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist
• Long experience in in-house commercial manufacturing • No risk of nitrosoamine presence -
Product Acetazolamide
Therapeutic Area: Cardiovascular system
EU DMF
US DMF
Korean DMF
Japanese DMF
CEP available
Available also in injectable form Indication: Acetazolamide decreases the pressure in the eye and is used for adjunctive treatment of glaucoma, a condition in which increa... -
Product Aripiprazole
Therapeutic Area: Nervous SystemEU DMF availableUS DMF no. 23314 availableCEP available Indication: used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression). It is also used together with other medications to treat major depressive disorder in adult... -
Product Carbamazepine
Therapeutic Area: Nervous System EU DMF availableUS DMF no. 26266 availableCEP available Indication: Carbamazepine is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder, as well as trigeminal neuralgia. -
Product Carvedilol
Therapeutic Area: Cardiovascular systemEU DMF availableUS DMF no. 17060 availableCEP available Indication: Carvedilol is a carbazole derivative acts as anti-hypertensive agent. It is formulated as tablets for oral route of administration. Carvedilol is indicated for the management of essential hypertens...
Polpharma Group Resources (1)
-
Brochure API Product List 2026
Thanks to over 75 years of experience in process development, scale-up and cGMP manufacturing, we support both emerging and established pharmaceutical customers in the development and commercialization of their small molecule API clinical candidates and CDMO service. At our FDA-approved plant located in Central Europe, we provide end-to-end solutions from API development to scale-up allowing smooth process transfer for commercial-scale manufacturing capabilities, with world-class regulatory support. Our strong R&D management team, experienced in the development of chemical processes and complex projects, provides a wide range of solutions to our customers, applying a variety of chemical reactions and conditions, including cryogenic, High Pressure, strong base reactions, and tailor-made particle size distribution modifications. At Polpharma quality comes first. Regular FDA audits prove our reliability and credibility towards business partners around the world.




